What is HC Wainwright’s Estimate for KPTI FY2024 Earnings?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Equities research analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Karyopharm Therapeutics in a report issued on Wednesday, January 15th. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($1.10) for the year, down from their prior estimate of ($1.06). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.21) EPS, FY2026 earnings at ($0.70) EPS and FY2027 earnings at ($0.04) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same period in the previous year, the firm posted ($0.30) earnings per share.

Other equities research analysts also recently issued research reports about the stock. Piper Sandler boosted their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock opened at $0.66 on Friday. The stock’s fifty day simple moving average is $0.75 and its 200 day simple moving average is $0.81. Karyopharm Therapeutics has a one year low of $0.58 and a one year high of $1.95. The firm has a market cap of $83.30 million, a price-to-earnings ratio of -0.58 and a beta of 0.07.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several large investors have recently made changes to their positions in KPTI. Point72 DIFC Ltd bought a new stake in Karyopharm Therapeutics during the 2nd quarter worth about $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth approximately $143,000. Acadian Asset Management LLC bought a new stake in shares of Karyopharm Therapeutics during the second quarter worth approximately $167,000. Exchange Traded Concepts LLC boosted its stake in Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after acquiring an additional 56,613 shares during the last quarter. Finally, FMR LLC boosted its stake in Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after acquiring an additional 76,510 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).